- Home
- MGRM vs CNTX Comparison
MGRM vs CNTX Comparison
Compare MGRM & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRM
- CNTX
- Stock Information
- Founded
- MGRM 2016
- CNTX 2015
- Country
- MGRM United States
- CNTX United States
- Employees
- MGRM N/A
- CNTX N/A
- Industry
- MGRM Medical/Dental Instruments
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- MGRM Health Care
- CNTX Health Care
- Exchange
- MGRM Nasdaq
- CNTX Nasdaq
- Market Cap
- MGRM 89.6M
- CNTX 77.2M
- IPO Year
- MGRM N/A
- CNTX 2021
- Fundamental
- Price
- MGRM $2.57
- CNTX $1.01
- Analyst Decision
- MGRM Strong Buy
- CNTX Strong Buy
- Analyst Count
- MGRM 1
- CNTX 5
- Target Price
- MGRM $4.00
- CNTX $6.70
- AVG Volume (30 Days)
- MGRM 63.8K
- CNTX 1.1M
- Earning Date
- MGRM 03-14-2025
- CNTX 11-06-2024
- Dividend Yield
- MGRM N/A
- CNTX N/A
- EPS Growth
- MGRM N/A
- CNTX N/A
- EPS
- MGRM N/A
- CNTX N/A
- Revenue
- MGRM $364,999.00
- CNTX N/A
- Revenue This Year
- MGRM N/A
- CNTX N/A
- Revenue Next Year
- MGRM N/A
- CNTX N/A
- P/E Ratio
- MGRM N/A
- CNTX N/A
- Revenue Growth
- MGRM N/A
- CNTX N/A
- 52 Week Low
- MGRM $1.53
- CNTX $0.89
- 52 Week High
- MGRM $4.90
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- MGRM 54.65
- CNTX 37.75
- Support Level
- MGRM $2.35
- CNTX $0.92
- Resistance Level
- MGRM $2.80
- CNTX $1.13
- Average True Range (ATR)
- MGRM 0.20
- CNTX 0.13
- MACD
- MGRM -0.01
- CNTX 0.01
- Stochastic Oscillator
- MGRM 54.00
- CNTX 20.00
About MGRM Monogram Orthopaedics Inc.
Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.